{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:14:40Z","timestamp":1778505280386,"version":"3.51.4"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T00:00:00Z","timestamp":1734825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"JSPS KAKENHI","award":["JP23K15773"],"award-info":[{"award-number":["JP23K15773"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This study aimed to assess the oncological outcomes of the subtype of urothelial carcinoma (SUC), including divergent differentiation and histologic subtype, in comparison with those of pure urothelial carcinoma (PUC) in nonmuscle-invasive bladder cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively evaluated patients who were initially treated with transurethral resection of the bladder tumor (TURBT) between March 2005 and August 2020 at a single institution. Patients with PUC and SUC were compared in terms of recurrence-free survival (RFS), progression-free survival (PFS), and overall survival (OS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Out of 853 enrolled patients, 783 (91.8%) and 70 (8.2%) had PUC and SUC, respectively. SUC presence was significantly associated with old age, tumor size (\u22653\u00a0cm), higher pT1 rate, high grade, concomitant carcinoma in situ, and lymphovascular invasion. RFS rates after TURBT did not significantly differ between the PUC and SUC groups. With a median follow-up period of 66\u00a0months (interquartile range, 38\u2013103\u00a0months), the rates and median time of progression to muscle invasion were 6.9% and 22.5\u00a0months in the PUC group, and 22.9% and 10.0\u00a0months in the SUC group. Moreover, the incidence of progression to metastasis was 4.6% and 15.7% in the PUC and SUC groups, respectively. The 5-year PFS rates (64.5% and 81.9%, P\u00a0&amp;lt; .001) and 5-year OS rates (71.7% and 86.2%, P\u00a0=\u00a0.009) were lower in the SUC group than in the PUC group. On multivariate analysis, SUC presence independently predicted progression to muscle invasion and metastasis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>At initial TURBT diagnosis, we must pay more attention to higher progression risk of SUC than that of PUC in nonmuscle-invasive bladder cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyae183","type":"journal-article","created":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T15:08:02Z","timestamp":1734880082000},"page":"414-420","source":"Crossref","is-referenced-by-count":3,"title":["Clinical impact of a subtype of urothelial carcinoma in nonmuscle-invasive bladder cancer"],"prefix":"10.1093","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6303-1128","authenticated-orcid":false,"given":"Akinori","family":"Minato","sequence":"first","affiliation":[{"name":"Department of Urology, School of Medicine, University of Occupational and Environmental Health , Kitakyushu ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moena","family":"Yoshii","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medicine, University of Occupational and Environmental Health , Kitakyushu ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuki","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medicine, University of Occupational and Environmental Health , Kitakyushu ,","place":["Japan"]},{"name":"Department of Urology, Kitakyushu City Yahata Hospital , Kitakyushu ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Moriya","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medicine, University of Occupational and Environmental Health , Kitakyushu ,","place":["Japan"]},{"name":"Department of Urology, Kyushu Rosai Hospital, Moji Medical Center , Kitakyushu ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Kashiwagi","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medicine, University of Occupational and Environmental Health , Kitakyushu ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medicine, University of Occupational and Environmental Health , Kitakyushu ,","place":["Japan"]},{"name":"Department of Urology, Kurate Hospital , Kurate ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,12,22]]},"reference":[{"key":"2025040711075687600_ref1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"2025040711075687600_ref2","author":"Globocan Bladder Cancer","year":"2020"},{"key":"2025040711075687600_ref3","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1097\/JU.0000000000001305","article-title":"A systematic review and meta-analysis of variant histology in urothelial carcinoma of the bladder treated with radical cystectomy","volume":"204","author":"Mori","year":"2020","journal-title":"J Urol"},{"key":"2025040711075687600_ref4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.21873\/cdp.10046","article-title":"Evaluation of the extent of variant histology in urothelial carcinoma as a predictive marker of clinical outcomes after radical cystectomy","volume":"1","author":"Minato","year":"2021","journal-title":"Cystectomy Cancer Diagn Progn"},{"key":"2025040711075687600_ref5","doi-asserted-by":"publisher","first-page":"873","DOI":"10.21873\/invivo.13513","article-title":"Efficacy of platinum-based chemotherapy in patients with metastatic urothelial carcinoma with variant histology","volume":"38","author":"Minato","year":"2024","journal-title":"In Vivo"},{"key":"2025040711075687600_ref6","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.euf.2019.09.003","article-title":"What is the significance of variant histology in urothelial carcinoma?","volume":"6","author":"Lobo","year":"2020","journal-title":"Eur Urol Focus"},{"key":"2025040711075687600_ref7","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.21873\/anticanres.14481","article-title":"The impact of histological variant on oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy","volume":"40","author":"Takemoto","year":"2020","journal-title":"Anticancer Res"},{"key":"2025040711075687600_ref8","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/JU.0000000000001325","article-title":"Pathological and survival outcomes associated with variant histology bladder cancers managed by cystectomy with or without neoadjuvant chemotherapy","volume":"205","author":"Hajiran","year":"2021","journal-title":"J Urol"},{"key":"2025040711075687600_ref9","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","article-title":"The 2022 World Health Organization classification of tumors of the urinary system and male genital organs-part B: Prostate and urinary tract tumors","volume":"82","author":"Netto","year":"2022","journal-title":"Eur Urol"},{"key":"2025040711075687600_ref10","doi-asserted-by":"publisher","first-page":"499.e1","DOI":"10.1016\/j.clgc.2022.05.001","article-title":"Efficacy of pembrolizumab in patients with variant urothelial carcinoma: A multicenter retrospective study","volume":"20","author":"Minato","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"2025040711075687600_ref11","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3390\/curroncol31020064","article-title":"Prognostic impact of histologic subtype and divergent differentiation in patients with metastatic urothelial carcinoma treated with enfortumab vedotin: A multicenter retrospective study","volume":"31","author":"Minato","year":"2024","journal-title":"Curr Oncol"},{"key":"2025040711075687600_ref12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2025040711075687600_ref13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.urology.2007.03.033","article-title":"Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection","volume":"70","author":"Wasco","year":"2007","journal-title":"Urology"},{"key":"2025040711075687600_ref14","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.urology.2014.06.032","article-title":"Concordance and clinical significance of uncommon variants of bladder urothelial carcinoma in transurethral resection and radical cystectomy specimens","volume":"84","author":"Cai","year":"2014","journal-title":"Urology"},{"key":"2025040711075687600_ref15","doi-asserted-by":"publisher","first-page":"278","DOI":"10.23736\/S2724-6051.23.05091-7","article-title":"European Association of Urology - young academic urologists (EAU-YAU): Urothelial carcinoma working group. Implications for diagnosis and treatment strategies in non-muscle invasive bladder cancer with variant histology: A systematic review","volume":"75","author":"Basile","year":"2023","journal-title":"Minerva Urol Nephrol"},{"key":"2025040711075687600_ref16","doi-asserted-by":"publisher","first-page":"161.e1","DOI":"10.1016\/j.urolonc.2024.01.009","article-title":"Prognostic impact of variant histology in bladder cancer: Would early and aggressive treatment shift the paradigm?","volume":"42","author":"Ramos","year":"2024","journal-title":"Urol Oncol"},{"key":"2025040711075687600_ref17","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.21873\/invivo.12968","article-title":"Squamous or glandular differentiation predicts poor prognosis in pT1 urothelial carcinoma","volume":"36","author":"Nakagawa","year":"2022","journal-title":"In Vivo"},{"key":"2025040711075687600_ref18","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.3390\/cancers13112615","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin treatment for T1 high-grade non-muscle invasive bladder cancer with divergent differentiation or variant morphologies","volume":"13","author":"Miyake","year":"2021","journal-title":"Cancer"},{"key":"2025040711075687600_ref19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fonc.2016.00043","article-title":"The response of variant histology bladder cancer to intravesical immunotherapy compared to conventional cancer","volume":"6","author":"Gofrit","year":"2016","journal-title":"Front Oncol"},{"key":"2025040711075687600_ref20","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.eururo.2018.11.052","article-title":"Micropapillary urothelial carcinoma of the bladder: A systematic review and meta-analysis of disease characteristics and treatment outcomes","volume":"75","author":"Abufaraj","year":"2019","journal-title":"Eur Urol"},{"key":"2025040711075687600_ref21","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.4081\/rt.2011.e22","article-title":"Is radical cystectomy mandatory in every patient with variant histology of bladder cancer","volume":"3","author":"Shapur","year":"2011","journal-title":"Rare Tumors"},{"key":"2025040711075687600_ref22","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.6004\/jnccn.2018.0079","article-title":"NCCN guidelines insights: Small cell lung cancer, version 2.2018","volume":"16","author":"Kalemkerian","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"2025040711075687600_ref23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.eururo.2019.09.035","article-title":"EAU-ESMO consensus statements on the Management of Advanced and Variant Bladder Cancer-an International Collaborative Multistakeholder Effort\u2020: Under the auspices of the EAU-ESMO guidelines committees","volume":"77","author":"Witjes","year":"2020","journal-title":"Eur Urol"},{"key":"2025040711075687600_ref24","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.urolonc.2022.02.004","article-title":"Histological variants of non-muscle invasive bladder cancer: Survival outcomes of radical cystectomy vs. bladder preservation therapy","volume":"40","author":"Dursun","year":"2022","journal-title":"Urol Oncol"},{"key":"2025040711075687600_ref25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2008.07.031","article-title":"Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology","volume":"55","author":"Shabsigh","year":"2009","journal-title":"Eur Urol"},{"key":"2025040711075687600_ref26","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/4\/414\/61253991\/hyae183.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/4\/414\/61253991\/hyae183.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T15:11:42Z","timestamp":1744038702000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/55\/4\/414\/7930335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,22]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,12,22]]},"published-print":{"date-parts":[[2025,4,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyae183","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,12,22]]}}}